These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 17189955

  • 21. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response.
    Marks LS, Roehrborn CG, Wolford E, Wilson TH.
    J Urol; 2007 Apr; 177(4):1408-13. PubMed ID: 17382742
    [Abstract] [Full Text] [Related]

  • 22. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 23. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia.
    Marberger M, Roehrborn CG, Marks LS, Wilson T, Rittmaster RS.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1323-8. PubMed ID: 16434455
    [Abstract] [Full Text] [Related]

  • 24. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK, Ross M, Tate R, Chisholm GD.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [Abstract] [Full Text] [Related]

  • 25. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
    Barkin J, Roehrborn CG, Siami P, Haillot O, Morrill B, Black L, Montorsi F, CombAT Study Group.
    BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
    [Abstract] [Full Text] [Related]

  • 26. [Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate].
    Boccon-Gibod L, Valton M, Ibrahim H, Boccon-Gibod L, Comenducci A.
    Prog Urol; 2005 Dec; 15(6):1085-9. PubMed ID: 16429657
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of dutasteride in Chinese adults with symptomatic benign prostatic hyperplasia: a randomized, double-blind, parallel-group, placebo-controlled study with an open-label extension.
    Na Y, Ye Z, Zhang S, Chinese Dutasteride Phase III Trial (ARIA108898) Study Group.
    Clin Drug Investig; 2012 Jan 01; 32(1):29-39. PubMed ID: 22017520
    [Abstract] [Full Text] [Related]

  • 28. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 29. Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Brown CT, Nuttall MC.
    Int J Clin Pract; 2003 Oct 01; 57(8):705-9. PubMed ID: 14627182
    [Abstract] [Full Text] [Related]

  • 30. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, REDEEM Study Group.
    Contemp Clin Trials; 2007 Nov 01; 28(6):763-9. PubMed ID: 17573244
    [Abstract] [Full Text] [Related]

  • 31. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G, Rittmaster RS, Klocker H.
    World J Urol; 2002 Apr 01; 19(6):413-25. PubMed ID: 12022710
    [Abstract] [Full Text] [Related]

  • 32. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM, Vis AN, van Moorselaar RJ, Bui HN, Blankenstein MA, Meuleman EJ, Heijboer AC.
    BJU Int; 2012 Jan 01; 109(2):176-82. PubMed ID: 21992222
    [Abstract] [Full Text] [Related]

  • 33. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
    Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B, Montorsi F, CombAT Study Group.
    J Urol; 2008 Feb 01; 179(2):616-21; discussion 621. PubMed ID: 18082216
    [Abstract] [Full Text] [Related]

  • 34. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy.
    Page ST, Hirano L, Gilchriest J, Dighe M, Amory JK, Marck BT, Matsumoto AM.
    J Urol; 2011 Jul 01; 186(1):191-7. PubMed ID: 21575967
    [Abstract] [Full Text] [Related]

  • 35. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
    Bartsch G, Rittmaster RS, Klocker H.
    Urologe A; 2002 Sep 01; 41(5):412-24. PubMed ID: 12426858
    [Abstract] [Full Text] [Related]

  • 36. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
    Iczkowski KA, Qiu J, Qian J, Somerville MC, Rittmaster RS, Andriole GL, Bostwick DG.
    Urology; 2005 Jan 01; 65(1):76-82. PubMed ID: 15667867
    [Abstract] [Full Text] [Related]

  • 37. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, Vis AN.
    BJU Int; 2012 Jan 01; 109(2):183-8. PubMed ID: 21992404
    [Abstract] [Full Text] [Related]

  • 38. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D.
    Zhonghua Wai Ke Za Zhi; 2000 Jul 01; 38(7):545-7. PubMed ID: 11832106
    [Abstract] [Full Text] [Related]

  • 39. Dutasteride significantly improves quality of life measures in patients with enlarged prostate.
    O'Leary MP, Roehrborn CG, Black L.
    Prostate Cancer Prostatic Dis; 2008 Jul 01; 11(2):129-33. PubMed ID: 17592479
    [Abstract] [Full Text] [Related]

  • 40. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991 Jul 01; 12(6):372-5. PubMed ID: 1722792
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.